How Much Did Affinity Biosensors Raise?
Funding & Key Investors

Affinity Biosensors, a company focused on rapid antimicrobial susceptibility testing (AST), has secured significant capital, with its total funding reaching $15.2M and its most recent financing round amounting to $1.6M. This major enterprise-level funding, characterized as a strategic investment, underscores the growing importance of efficient diagnostic solutions in combating antimicrobial resistance.

What is Affinity Biosensors?

Affinity Biosensors
ManufacturingTest & Measurement EquipmentMedical Devices & Equipment

Affinity Biosensors specializes in the development and deployment of advanced diagnostic technologies, notably its LifeScale system. This platform leverages population profiling technology to deliver rapid and accurate antimicrobial susceptibility testing (AST) results in approximately 4 hours. Designed for laboratory environments, the LifeScale system aims to enhance patient care by providing critical-care situations with faster insights into pathogen resistance, thereby streamlining treatment decisions. The company's focus on user-friendly integration into existing laboratory workflows highlights its commitment to practical and efficient clinical solutions.

How much funding has Affinity Biosensors raised?

Affinity Biosensors has raised a total of $15.2M across 6 funding rounds:

2013

Private Equity

$1.3M

2016

Series A

$7.1M

2017

Private Equity

$4.8M

2020

Debt

$150K

2021

Debt

$347K

2026

Private Equity

$1.6M

Private Equity (2013): $1.3M, investors not publicly disclosed

Series A (2016): $7.1M, investors not publicly disclosed

Private Equity (2017): $4.8M, investors not publicly disclosed

Debt (2020): $150K featuring PPP

Debt (2021): $347K backed by PPP

Private Equity (2026): $1.6M, investors not publicly disclosed

What's next for Affinity Biosensors?

The substantial enterprise-level capital infusion and recent strategic investment position Affinity Biosensors for accelerated growth and market penetration. This backing is expected to fuel further development of its LifeScale AST system, potentially expanding its capabilities and reach within the global healthcare diagnostics market. The company is poised to enhance its role in addressing the critical challenge of antimicrobial resistance, with future initiatives likely focusing on scaling production, broadening its customer base, and potentially exploring new applications for its population profiling technology. This strategic financing signals strong confidence in Affinity Biosensors' mission to revolutionize laboratory diagnostics.

See full Affinity Biosensors company page
See More Financial Insights
No matching results.
Refine your search.

Additional financial insights in the Manufacturing industry

FurnitureManufacturing
Industrial Machinery & EquipmentManufacturingElectronics
Industrial Machinery & EquipmentManufacturing
Industrial Machinery & EquipmentManufacturing

Frequently Asked Questions Regarding Affinity Biosensors Financial Insights

What are the most recent funding rounds that Affinity Biosensors has completed, and what were the funding rounds?
Affinity Biosensors has recently completed 3 funding rounds: Private Equity on Mar 23, 2026, Debt on Jan 29, 2021, Debt on Apr 15, 2020.
What is the total amount of funding Affinity Biosensors has raised to date?
Affinity Biosensors has raised a total of $15.2M in funding to date.
How many funding rounds has Affinity Biosensors completed?
Affinity Biosensors has completed 3 funding rounds.
How much funding did Affinity Biosensors raise in its most recent funding round?
Affinity Biosensors raised $1.6M in its most recent funding round.
Which was the largest funding round in Affinity Biosensors's history?
The largest funding round in Affinity Biosensors's history was $7.1M.
See more information about Affinity Biosensors